# Appropriate disclosure of product/service information

We're developing centralized systems for managing information on product/service quality and safety. We also analyze customer feedback and questions, and strive to disclose and share it in a timely and appropriate manner with management and staff.

## **Clear and accurate test results**

Conveying information clearly and accurately is a crucial part of providing laboratory services to medical institutions. SRL takes care to ensure that test results are easy for patients to understand, and easy for doctors to explain. For example, for cancer risk screenings that use the AminoIndex Technology, offered by SRL since 2011, additional material is provided explaining how to interpret the test results.


By providing information in this way, SRL contributes to a healthy and prosperous society.

					がんり		リインテ	ックス。 ブ (AICS	.)の解
					検索結果(	AICS	227) 1236	31	
このたび、受診いただきましたあなたのAICS・検査拡要および 現在がんである可能性をご解告させていただきます。 構成のである可能性をご解告させていただきます。 構成のである可能性をご解告させていただきます。				F	Aには幅は、それぞれのがんについて、供自分人である考慮的を、0.0-10. 物質で得しています。加速が用いなど、用空が人である可能が加えて ます。用ながったもある理由が不同させないである。あたのうかの少少 分類しています。AにSaでは、ラングA・ラングB・ラングCの調査です がんである可能が知らないます。 4902/000/blocemat Disc. 40-14-145				
					523	791	522A	5228	5220
					AN	540	0.0-4.9	5.0~7.9	8.0-10.
					AL108	BUL.	1/82000.08E	1162013-640	1/14030-346
					Holes	81%	(Conditionant)	-frikalize and	Intibiée
Contraction of the	La contra da	A Designable state form	Contract Property and	and the second second	ACLAND	ARTS	1/2.00008.000	- 17999153483	007318-38
Sector and the sector of	PT CONTRACTOR	d Lawrined and here	correct for even	Provide Name	ACCURATE	ABRILL	1/2.00010.580 1/2.42400.380	1/989(1.388)	
■ がんである可 Eい	PT CONTRACTOR	#AC#6588	const. Intercon		and the second se	1	and the second se	and the second se	100011Am
がんである可 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	RTE	1/A 7 8 5 981	327 33	7004	Actual	Mars.	1/24040380	1//0011-3001	tastrilas intega as
がんである可	AD35 B	52280A 10.000A035	327 33	-	Actions Activities	REFL BORNS	1/2-Rootstader Fristansingen	1/98011388 1-66012-191	1972 page 1988 Page Aug 1999 Page Aug 1999 Page Aug 1999 Page Aug
がんである可 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	AD25 7. 125	522804 1022804 1034-214	Č 40.	-116x	Actions Actions Actions Actions Actions Actions Actions	8875 83875 875 7875-8875	1/6.42400.380 1/6.22200.580 1/4.00000.380 0/4.00000.380	1/70011-3400 1-444912-1001 1-05443.0000	Labort Las Lothaga An Lothaga An Lothaga An Lothaga An
がんである可 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	AQ.L. 922 AD75 B -7 B CONCIMENTERS	#AD660mm 92280A 92280A 102600A095 13,~21,4	Č 40.	**************************************	Actings Actings Actings Acting	1007% 0200% 87% 100% 000% 100% 000% 100% 000% 100% 000% 100% 1	1/242403.380 1/232003.680 1/450003.080 1/45003.080 1/45000000000000000000000000000000000000	IVIDIII300 Ividalizingi Ividalizingi Ividalizingi Ividaliangi Ivid	LUBATTAN Inthone Ann Inthone Ann Inthone Ann
	ана 2022 Авал 2025 Авал 2025 Верика Семетика С Семетика Семетика С Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика С С С Семетика С С С С С С С С С С С С С С С С С С С	10000000 0000000 13.~21.c	227 120 120 40.	2004 2004 2005 200 200	E. Tuniti - State and a state and a state and a state a state a state a state a state a state a state a state a state a state state state state state state state state state state st	1007% 02007% RFA 9007%-0007% 000404000 000400000 0004000000 00140000000 001400000000	(124200.48) (122201.68) (122201.68) (126001.48) (12600	IVIDIII300 Ividalizingi Ividalizingi Ividalizingi Ividaliangi Ivid	Lobert Am Lobert Am Lobert Am Lobert Am Angel Market Marke
**************************************	ана 2022 Авал 2025 Авал 2025 Верика Семетика С Семетика Семетика С Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика С С С Семетика С С С С С С С С С С С С С С С С С С С	1000000000 1000000005 132-212 132-212 132-212 100000000000 100000000000 1000000000		жы жала жала таба жала жала жала жала жала жала жала ж	Activity Act	нать еслить RPA Рапо-радов Рапо-радов Рапо-радов от само рабо от	(124200.48) (122201.68) (122201.68) (126001.48) (12600	Investiges Investiges	Lobert Am Lobert Am Lobert Am Lobert Am Angel Market Marke
**************************************	ана 2022 Авал 2025 Авал 2025 Верика Семетика С Семетика Семетика С Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика Семетика С С С Семетика С С С С С С С С С С С С С С С С С С С	1000000000 1000000005 132-212 132-212 132-212 100000000000 100000000000 1000000000				нать		Investiges Investiges	Laurian Integration Internation
**************************************	ала Абл. Абл. Абл. Абл. Абл. Абл. Абл. Абл.	1000000000 1000000005 132-212 132-212 132-212 100000000000 100000000000 1000000000	200 100 400.		Action Actional Actio	анать водать клам тратьскаять клам тратьскаять клам тратьскаять клам тратьскаять клам тратьскаятьскаяться тратьскаятьскаяться тратьскаять тратьск			tauritan intaga an intega

## LUMIPULSE® control survey

Every year, Fujirebio conducts a control survey and holds a quality control reporting conference to ensure high testing quality at all medical institutions in Japan that use the LUMIPULSE® system. As of July 2018, the survey has been held 25 times and the conference 24 times. Of the 1,120 LUMIPULSE® systems installed across Japan, 895 facilities participated in total. In addition to quality improvements at laboratories, Fujirebio will also continue to proactively disclose and provide essential information for further improving the performance of its reagents.

Participation rate in control survey and reporting conference



#### What is a control survey?

Compared to "internal quality controls" conducted by laboratories themselves, a control survey is a method of "external quality controls" which a lab's test data are analyzed in comparison to a certain minimum of test data obtained from other labs. Manufacturers use this method to improve the performance of tests at each facility where its devices are used. [Background information]

Each clinical laboratory makes routine efforts to produce accurate test results for patients. However, the conditions in which each testing is carried out are not always uniform, creating potential variations in results.

#### [Benefits]

This comparison of data can help improve testing conditions and the performance of reagents used.